« Return to News | Clinical Intelligence

Biodel plans insulin trials

Wednesday, March 16, 2011 01:56 PM

Biodel has selected two new formulations of recombinant human insulin for clinical testing and is accelerating clinical development plans of these mealtime insulin drug candidates.  The new formulations, BIOD-105 and BIOD-107, are designed to result in more rapid insulin action compared to currently marketed meal time insulin analogs while maintaining an injection site tolerability profile comparable to currently marketed insulins.  Biodel plans to test these formulations in a phase I clinical trial of approximately 18 patients with Type I diabetes.

This study is designed as a double-blinded, three-period, cross-over trial in which patients will receive one subcutaneous injection of BIOD-105,BIOD-107 and HumalogR each on separate occasions.  This study, expected to be completed in the third quarter of 2011, will evaluate pharmacokinetic, pharmacodynamic and tolerability profiles of the two experimental insulins relative to that of HumalogR. 

If this phase I study is successful, Biodel anticipates initiating a phase II study in patients with Type I diabetes in the fourth calendar quarter of 2011.  The phase II study is intended to follow the same overall design that would be implemented in phase III studies, which would include two separate pivotal trials—one in patients with Type I diabetes, and the other in patients with Type II diabetes. 

If the results of the phase II testing are successful, the company plans to launch phase III pivotal studies in 2012.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.